T. Rowe Price Investment Management
HZNP

T. Rowe Price Investment Management’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

T. Rowe Price Investment Management’s Portfolio HZNP Stock Details HZNP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-3,029,711
Closed -$331M – 596
2023
Q1 		$331M Sell
3,029,711
-1,020,548
-25% -$113M 0.24% 116
2022
Q4 		$461M Buy
+4,050,259
New +$336M 0.35% 81

Other funds holding HZNP

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $9.85B AUM 55.6% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

T. Rowe Price Investment Management's HZNP Position: Q2 2023 in Review

T. Rowe Price Investment Management sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q2 2023, closing a stake of 3,029,711 shares — an estimated $331M sold.

T. Rowe Price Investment Management first reported a position in HZNP in Q4 2022 and held it in 2 quarters. The position peaked at $461M in Q4 2022. 519 funds tracked by Wall St. Rank hold HZNP as of Q2 2023.

  • T. Rowe Price Investment Management reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q2 2023 after selling out during the quarter.
  • T. Rowe Price Investment Management sold 3,029,711 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q2 2023, an estimated $331M.
  • T. Rowe Price Investment Management first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q4 2022 and held it in 2 quarters.
  • T. Rowe Price Investment Management's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $461M in Q4 2022.
  • 519 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q2 2023.

Based on T. Rowe Price Investment Management's 13F filing for Q2 2023, filed 14 Aug 2023.